Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: WMT stock price vs MRNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRNA's multiple
Needs MRNA P/E.
Implied fair value · at WMT's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 95% equity / 5% debt · EV / Revenue 1.29x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WALMART INC. · implied price per share
Bear
$26.01
Base
$31.42
Bull
$38.87
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TARGET CORP
WMT vs TGT
Costco Wholesale Corporation
WMT vs COST
Amazon.com, Inc.
WMT vs AMZN
CVS Health Corporation
WMT vs CVS
Walgreens Boots Alliance, Inc.
WMT vs WBA
DOLLAR GENERAL CORP
WMT vs DG
PFIZER INC
WMT vs PFE
JOHNSON & JOHNSON
WMT vs JNJ
GILEAD SCIENCES, INC.
WMT vs GILD
AMGEN INC
WMT vs AMGN
NOVAVAX INC
WMT vs NVAX
VERTEX PHARMACEUTICALS INC / MA
WMT vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe WMT can continue its 4.7% revenue growth and 22.8% ROIC while MRNA's negative growth and margin profile persist, then favor WMT because MRNA-implied valuation gap is not supported by the current operating data.
The valuation gap is extreme: WMT trades at $113.86 versus an implied price of $838.06, suggesting 636.0% upside on the P/S comparison. That gap is driven by WMT's low 1.3x P/S and 1.3x EV/Revenue versus MRNA's 9.4x P/S and 8.3x EV/Revenue, despite WMT's far stronger operating profile.
Supporting Metrics
